These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
100 related articles for article (PubMed ID: 6220024)
1. Quantitative determination of cardiotonic agent MDL 17,043 in plasma by reversed-phase high-performance liquid chromatography. Chan KY; Lang JF; Okerholm RA J Chromatogr; 1983 Feb; 272(2):396-400. PubMed ID: 6220024 [No Abstract] [Full Text] [Related]
2. Simultaneous analysis of a new cardiotonic agent, MDL 17,043, and its major sulfoxide metabolite in plasma by high-performance liquid chromatography. Chan KY; Ohlweiler DF; Lang JF; Okerholm RA J Chromatogr; 1984 Mar; 306():249-56. PubMed ID: 6232282 [TBL] [Abstract][Full Text] [Related]
3. [Determination of enoximone and its principle metabolite in serum and urine using high pressure liquid chromatography]. Tarral E; Jehl F; Gallion C; Monteil H Therapie; 1990; 45(1):1-6. PubMed ID: 2140472 [TBL] [Abstract][Full Text] [Related]
4. Automatic preparation of human serum samples for analysis of the drug enoximone and its sulphoxide metabolite using high-performance liquid chromatography. Cooper JD; Turnell DC J Chromatogr; 1986 Jul; 380(1):109-16. PubMed ID: 2943750 [TBL] [Abstract][Full Text] [Related]
5. High-performance liquid chromatographic assay of 2-[2-methoxy-4-(methylsulfinyl)phenyl]-1H-imidazo-[4,5-c] pyridine hydrochloride, a potent cardiotonic agent, and two metabolites in plasma. Bernstein JR; Franklin RB J Chromatogr; 1985 Jul; 342(1):228-33. PubMed ID: 3840172 [No Abstract] [Full Text] [Related]
6. Method of analysis of the new cardiotonic agent, MDL 19,205, in plasma and urine and its application in a dog pharmacokinetic study. Keeley FJ; Theile JD; Garteiz DA; Weiner DL; Okerholm RA J Chromatogr; 1983 Dec; 278(2):379-85. PubMed ID: 6668317 [TBL] [Abstract][Full Text] [Related]
7. Cardiovascular properties of a new cardiotonic agent: MDL 17,043 (1.3-dihydro-4-methyl-5-[4-(methylthio)-benzoyl]-2H-imidazol-2-one). Dage RC; Roebel LE; Hsieh CP; Weiner DL; Woodward JK J Cardiovasc Pharmacol; 1982; 4(3):500-8. PubMed ID: 6177949 [TBL] [Abstract][Full Text] [Related]
8. Positive inotropic therapy for short-term support and long-term management of patients with congestive heart failure: hemodynamic effects and clinical efficacy of MDL 17,043. Uretsky BF; Valdes AM; Reddy PS Circulation; 1986 Mar; 73(3 Pt 2):III219-29. PubMed ID: 2935328 [TBL] [Abstract][Full Text] [Related]
9. Biotransformation and pharmacokinetic overview of enoximone and its sulfoxide metabolite. Okerholm RA; Chan KY; Lang JF; Thompson GA; Ruberg SJ Am J Cardiol; 1987 Aug; 60(5):21C-26C. PubMed ID: 2956863 [TBL] [Abstract][Full Text] [Related]
10. Determination of 4,5-dihydro-6-[4-(1H-imidazol-1-yl) phenyl]-3(2H)-pyridazinone hydrochloride, a new cardiotonic, in plasma and urine by reversed-phase high-performance liquid chromatography. Hayes AG; Mehta S; Chang T J Chromatogr; 1984 Dec; 336(2):446-51. PubMed ID: 6530478 [No Abstract] [Full Text] [Related]
11. Comparison of two high-performance liquid chromatographic methods for the determination of oxmetidine and its metabolites in plasma, bile and urine samples. Lee RM; McDowall RD J Chromatogr; 1983 Apr; 273(2):335-45. PubMed ID: 6863448 [TBL] [Abstract][Full Text] [Related]
12. Determination of the antifungal agent, ketoconazole, in human plasma by high-performance liquid chromatography. Alton KB J Chromatogr; 1980 Dec; 221(2):337-44. PubMed ID: 6260830 [TBL] [Abstract][Full Text] [Related]
13. Human serum and plasma protein binding of enoximone and its sulfoxide metabolite. Hook RH; Boxenbaum H; Thompson GA; Okerholm RA J Pharm Sci; 1988 Dec; 77(12):1012-7. PubMed ID: 3244103 [TBL] [Abstract][Full Text] [Related]
14. Cardiovascular properties of a new cardiotonic agent, MDL 19205. Dage RC; Roebel LE; Hsieh CP; Woodward JK J Cardiovasc Pharmacol; 1984; 6(1):35-42. PubMed ID: 6199609 [TBL] [Abstract][Full Text] [Related]
15. High-performance liquid chromatographic determination of angiotensin II receptor antagonists in human plasma and urine. I. DuP 532 (L-694,492). Chiou RH; Lo MW J Chromatogr; 1992 Oct; 581(1):165-70. PubMed ID: 1430003 [TBL] [Abstract][Full Text] [Related]
16. Determination of carnosine and other biogenic imidazoles in equine plasma by isocratic reversed-phase ion-pair high-performance liquid chromatography. Dunnett M; Harris RC J Chromatogr; 1992 Aug; 579(1):45-53. PubMed ID: 1447350 [TBL] [Abstract][Full Text] [Related]
17. The influence of various degrees of cardiac failure, chronic medical treatment, and acute additional enoximone application on the parameters of the vasopressor system. Mitrovic V; Neuzner J; Husseini H; Volz M; Schlepper M J Cardiovasc Pharmacol; 1989; 14 Suppl 1():S40-9. PubMed ID: 2480485 [TBL] [Abstract][Full Text] [Related]
18. Electrophysiologic effects of enoximone in patients with congestive heart failure. Hohnloser SH; Zehender M; Geibel A; Meinertz T; Just H J Cardiovasc Pharmacol; 1989; 14 Suppl 1():S29-32. PubMed ID: 2480482 [TBL] [Abstract][Full Text] [Related]
19. Effects of a new cardiotonic agent, MDL-17,043, on myocardial contractility and left ventricular performance in congestive heart failure. Strain J; Grose R; Maskin CS; LeJemtel TH Am Heart J; 1985 Jul; 110(1 Pt 1):91-6. PubMed ID: 3160228 [TBL] [Abstract][Full Text] [Related]
20. Pharmacology of enoximone. Dage RC; Kariya T; Hsieh CP; Roebel LE; Cheng HC; Schnettler RA; Grisar JM Am J Cardiol; 1987 Aug; 60(5):10C-14C. PubMed ID: 2956861 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]